BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Alkermes plc (ALKS)Alkermes plcEarnings

DUBLIN --(BUSINESS WIRE)--Feb. 25, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please

Related news

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

VTGNVistagen Therapeutics, Inc.2026-08-14 12:32 EST

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

CLNNClene Inc.2026-08-14 12:30 EST

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-08-24 22:30 EST

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

ALKSAlkermes plc2026-07-13 11:00 EST

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

ALKSAlkermes plc2026-06-17 20:15 EST

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Stock data

Close
48.33 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States